Tanya M. Trippett, MD
Pediatric Hematologist-Oncologist
Titles
Associate Attending Pediatrician
Clinical Expertise
Pediatric Oncology; Hodgkin and Non-Hodgkin Lymphoma; Leukemias; New Investigational Agents; Drug Resistance
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Trippett accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 212-639-8267 Office Phone
- Speaks English
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Duke University School of Medicine
Residencies
Pediatrics - Duke University Medical Center
Fellowships
Pediatric Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
Pediatrics; Pediatric Hematology-Oncology
As a member of the MSK Kids team, I specialize in the care of children with leukemia and lymphoma, especially cancers that have returned despite prior treatment. I also conduct clinical research to design and assess investigational therapies — particularly antibodies and new targeted agents that aim at the molecular signaling pathways that drive cancer growth — for children with all types of cancer.
Read more
I have a background in molecular pharmacology and translational research, especially studies of the molecular mechanisms of drug resistance. I believe that understanding the fundamental biology of cancer is vital to our ability to improve cancer treatment. The work we’ve done in the laboratory and its translation to improve the treatment of lymphoma is now being applied to the care of children with diverse types of cancer. This is very satisfying for me and serves as a tribute to the patients we’ve treated. Research enables us to provide options to patients when none are available, giving patients and parents hope.
I previously served on the national level in the Children’s Oncology Group, where I served as Chairperson of the Hodgkin’s Biology Committee and Vice Chair of the Hodgkin’s Disease Committee for 12 years. I also teach and mentor fellows who have gone on to start their own research programs.
I am the Co-Founder of Pediatric Oncology Experimental Therapeutics Investigator Consortium (POETIC), a collaboration between multiple centers around the country, whose mission is the development of biologically targeted therapies for cancers that have recurred in children. I started POETIC in February 2003 to increase patients’ access to promising new agents in clinical trials. I served as Director of the POETIC Coordinating Center at Memorial Sloan Kettering, the only POETIC center in New York City from inception to 2019.
I am now pursuing a broader interest in global disparities in cancer care for children in limited resource nations outside the United States for which I have developed a new initiative under the Global Disparities Program at MSK. I am leading a team of professionals to build a children’s cancer center in Ghana. I formed a charitable humanitarian organization to help with this initiative.
It is very gratifying when I see patients conquer cancer and go on to do well. I understand how critical research is to advancing the treatment of cancer, and it is rewarding to know that the investigations I am leading may save the life of a child.
- Clinical Expertise: Pediatric Oncology; Hodgkin and Non-Hodgkin Lymphoma; Leukemias; New Investigational Agents; Drug Resistance
- Awards and Honors: Castle Connolly: New York Magazine Top Doctors (2013-2018)
- Languages Spoken: English
- Education: MD, Duke University School of Medicine
- Residencies: Pediatrics - Duke University Medical Center
- Fellowships: Pediatric Hematology/Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Pediatrics; Pediatric Hematology-Oncology
Awards and Honors
- Exceptional Women in Medicine Award, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2013-2018)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Trippett
- A Phase I Study of Idasanutlin Alone or with Chemotherapy in Pediatric and Young Adult Patients with Recurrent or Persistent Solid Tumors
- A Phase I/II Study of Neratinib in Children and Adolescents with Recurrent or Persistent Cancer
- Clinical Trials Co-Investigated by Dr. Trippett
- A Phase II Study of Brentuximab Vedotin with Chemotherapy and Immunotherapy in People with Classical Hodgkin Lymphoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Trippett’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Tanya M. Trippett discloses the following relationships and financial interests:
-
Eugene Gasana Jr. Foundation
Fiduciary Role/Position
-
Genentech
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
